IL1A and neoplasm: In addition, treatment of melanoma with VEM was reported to inhibit BRAFV600E-induced IL-1 (interleukin 1) production by melanoma cells and thereby to diminish IL-1 dependent production of protolerogenic prostaglandins and PD-L1/2 in the tumor micro-environment [14].